Amvuttra® (vutrisiran)

Amvuttra is covered for adults (≥18) for FDA‑approved hereditary transthyretin‑mediated (hATTR) polyneuropathy and for wild‑type or hereditary transthyretin cardiomyopathy, excluded for patients <18, for hATTR polyneuropathy with prior liver transplant, for cardiomyopathy with NYHA class IV, and not covered for non‑FDA indications. Approval requires documented evidence (polyneuropathy: TTR pathogenic variant by genetic testing, symptomatic polyneuropathy, and neurologist/geneticist/amyloidosis specialist prescriber/consult; cardiomyopathy: PYP scan OR biopsy with TTR typing OR genetic confirmation plus imaging showing cardiac involvement, heart failure not NYHA IV, and cardiologist/amyloidosis specialist prescriber/consult), dosing of 25 mg SC every 3 months, and is authorized for up to 12 months.

"the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults"